We attempted to administer PEG-L-asparaginase (PEG-L-A) following hematologic recovery to 38 patients undergoing autologous or allogeneic marrow transplantation for acute lymphoblastic leukemia (ALL). Twentyfour patients ( Relapse is the predominant cause of treatment failure in pediatric patients undergoing allogeneic or autologous bone marrow transplantation for acute lymphoblastic leukemia (ALL) beyond first remission. Relapse rates of 20-50% have been reported for patients undergoing allogeneic BMT and 50-80% for patients undergoing autologous BMT for advanced ALL. [1] [2] [3] [4] [5] Attempts to reduce the frequency of leukemic recurrence by intensification of preparative regimens
for bone marrow transplantation have occasionally been successful, but usually at the price of higher morbidity and mortality rates, since most preparative regimens employ maximal or near maximal radiation and chemotherapy doses. [6] [7] [8] Other strategies for reducing relapse have been explored. Since the development of graft-versus-host disease (GVHD) in some series of allogeneic BMT has been associated with a diminished relapse rate, [9] [10] [11] [12] Sullivan et al 13 restricted prophylaxis in order to promote an antileukemic effect, but found a higher rate of severe GVHD and no improvement in overall disease-free survival. Recent trials in autologous marrow transplantation attempting to induce a graft-versus-leukemia effect have focused on the use of immune-modulators such as cyclosporin A, 14, 15 interferon alpha-2b, 16, 17 linomide, 18 and interleukin-2. [19] [20] [21] The value of these therapies continues to be explored.
Results from the International Bone Marrow Transplant Registry 22 suggested that the use of methotrexate as posttransplant GVHD prophylaxis was associated with a diminished relapse rate, and led some groups to question if post-BMT chemotherapy might be useful. Weisdorf et al 10 attempted to deliver chemotherapy with 6-mercaptopurine (6-MP) and methotrexate (MTX) to patients undergoing allogeneic BMT for ALL following hematopoietic reconstitution. Patients were randomized to receive further therapy with oral 6-mercaptopurine, 50 mg/m 2 /day and methotrexate 10 mg/m 2 /week. Patients randomized to post-transplant chemotherapy received an average of only 60% of the intended chemotherapy, and the authors concluded there was no benefit to receiving the additional treatment (seven of 13 relapses after or during chemotherapy as opposed to six of 14 relapses in patients receiving none). Tiley et al 23 administered 6-MP and MTX to 26 patients of a group of 38 who had undergone autologous BMT for high-risk ALL in first remission. Patients tolerated about 50% of the projected treatment. The authors noted a 5-year survival of 49% in this population, similar to that of a group of patients treated with chemotherapy without ABMT, but could not determine the contribution of the maintenance therapy to event-free survival.
An agent useful for post-transplant chemotherapy would ideally have little myelosuppressive effect (so as not to endanger the marrow graft), would not show cross-resist-ance with the agents used for the transplant regimen and would be one to which most patients' leukemia would still be sensitive. l-Asparaginase may be such an agent. Although it is moderately immunosuppressive, [24] [25] [26] it is usually not myelosuppressive; 27 it has a unique mechanism of action among available agents, 28 and no evidence of cross-resistance to other anti-cancer drugs. Although almost all relapsing ALL patients will have received the drug previously, l-asparaginase can be used repeatedly as part of successful remission induction, [29] [30] [31] suggesting that past exposure does not preclude an antileukemic response.
Based on this rationale, we undertook a trial of posttransplant PEG-l-asparaginase (PEG-L-A) for patients undergoing allogeneic or autologous BMT for ALL. PEG-L-A was particularly attractive as a post-BMT agent because its diminished immunogenicity [32] [33] [34] might result in a lower allergy rate for patients with reconstituting immune systems and because its sustained activity after administration might allow for fewer injections than conventional formulations. [35] [36] [37] [38] We describe below a pilot study which attempted to determine, specifically: (1) whether PEG-L-A could be administered following recovery from allogeneic or autologous BMT in patients with acute lymphoblastic leukemia; (2) the toxicity of PEG-L-A in this group of patients; and (3) the asparaginase pharmacokinetics following the first dose in this group of patients.
Patients and methods

Patients
Between 1 November 1990 and 1 January 1995, 30 pediatric patients with early B-lineage ALL underwent autologous (n = 16) or non-T cell-depleted, family donor-matched allogeneic (n = 14) BMT at the Duke University Medical Center. In addition, eight patients underwent family donormatched allogeneic BMT for T cell malignancy, and were included in this trial. Characteristics of this group of 38 patients are noted in Table 1 .
Patients were eligible for BMT on this protocol if they had: (1) normal cardiac function (normal ECG, ejection fraction Ͼ45% or shortening fraction Ͼ28% by echocardiogram); (2) normal hepatic function (bilirubin Ͻ1.5 mg/dl, transaminases Ͻ2 times normal); (3) adequate renal function (creatinine Ͻ1.5 mg/dl); and (4) normal pulmonary function (FVC and FEV 1 Ͼ75% of predicted or, for children unable to comply with testing, a crying vital capacity Ͼ75% of predicted).
Marrow procurement and processing
Patients undergoing autologous BMT had bilateral marrow aspirates to determine that they were in complete remission. They then had 3-5 × 10 8 nucleated marrow cells per kg harvested, except for two patients in whom previous harvests precluded successful procedures; these two underwent growth factor-primed peripheral stem cell harvests. Autologous marrows and stem cells were purged with anti-CD19 and anti-CD20 antibodies (Biosource, Camarilla, CA, 
Preparative regimens
Twenty-one patients received intravenous melphalan, 50-90 mg/m 2 over 1 h as a single infusion on day −9, total body irradiation, 150 cGy twice a day × 9, days −8 to −4 and cyclophosphamide 2.4 g/m 2 /day, days −3 and −2. Eleven received total body irradiation, 150 cGy twice a day × 9, days −8 to −4, and cyclophosphamide 2.4 g/m 2 /day, days −3 and −2. Three received busulfan, 37.5 mg/m 2 /dose every 6 h for 16 doses, days −7 to −4, and intravenous melphalan, 180 mg/m 2 over 1 h on day −2. Two received busulfan, 40 mg/m 2 /dose every 6 h for 16 doses, days −9 to −6 and cyclophosphamide, 50 mg/kg/day, days −5 to −2. One patient received melphalan 140 mg/m 2 over 1 h on day −5 and total body irradiation, 150 cGy twice a day × 9 doses, days −4 to 0 (the last dose given 6 h prior to marrow infusion). Total body irradiation was delivered by a 4 MV linear accelerator at extended distance to deliver approximately 13 cGy per minute. On each of the first 2 days of radiotherapy treatment, males received once daily dosing of 2 cGy to the testes. In addition, seven patients whose indication for BMT included a central nervous system relapse received additional cranial (900-1080 cGy) and spinal (260-900 cGy) radiotherapy boosts in the week before the start of preparative therapy.
Patients were nursed on the Duke University Pediatric Bone Marrow Transplant Unit in hepafiltered rooms. All patients received transfusion, antibiotic, and nutritional support according to accepted practice. Patients undergoing allogeneic BMT received GVHD prophylaxis with cyclosporin A for 6 months and methotrexate for up to four doses.
Study design
Although the ultimate purpose of post-transplant chemotherapy would be to improve disease-free survival, the number of patients treated in this study was too small to make a statement of antileukemic efficacy. This was a pilot protocol whose purposes were to attempt to study the toxicity, pharmacokinetics, and likelihood of administration of PEG-L-A in patients following transplantation for ALL.
Eligibility for asparaginase treatment
Patients or their parents were required to give informed consent for this treatment protocol, which was approved by the Duke University Medical Center Institutional Review Board. In order to receive PEG-L-A, all patients were required to have recovered from mucosal toxicity from the preparative regimen, not to have had recent pancreatitis or severe veno-occlusive disease, to have absolute neutrophil counts above 200 and platelet counts above 50 000, be in documented marrow remission, and be at least 30 days beyond marrow transplantation. The reasons why 14 of the 38 patients did not receive PEG-L-A are listed in Table 2 .
Initiation of treatment
PEG-L-A was dosed at 2500 IU/m 2 /dose and given intramuscularly every 14 days for up to 12 doses. It was to be discontinued for relapse, hypersensitivity, or grade IV (lifethreatening) toxicity. Of the 16 patients who underwent autologous BMT, 12 (75%) were able to begin PEG-L-A a median of 55 days (range 34-70) after transplantation. Of the 22 patients who underwent allogeneic BMT, 12 (55%) were able to begin PEG-L-A a median of 46 days (range 32-75 days) after transplantation. There were no statistically significant differences by 2 testing for patients receiving or not receiving PEG-L-A with regard to gender (P = 0.51), disease status (P = 0.473), disease (B-lineage vs T cell leukemia), or preparative regimen (P = 0.705) ( Table  1 ). There was a trend toward younger age in patients receiving PEG-L-A (mean 8.7 ± 5.2 years for those receiving it, 12.0 ± 5.0 years for those not), possibly reflecting a higher rate of certain transplant complications among older patients.
The limiting eligibility criterion for starting PEG-L-A was usually the requirement for platelets of 50 000/l. Of the six patients (three autologous, three allogeneic) who eventually began treatment but not until after day +60, delays were due to slow platelet recovery (three autologous), cyclosporin A toxicity resulting in a seizure and thrombocytopenia (one allogeneic), thrombocytopenia accompanying mild GVHD (one allogeneic), and viral cystitis (one allogeneic). 
Pharmacologic studies
First dose pharmacokinetics and anti-asparaginase antibody titers were measured in 19 and 15 patients, respectively, using previously established methods. 35, 39, 40 Pre-dose asparaginase and asparagine levels were obtained on day 1 of PEG-L-A administration, followed when possible by levels on days 2-5, 8-12, 15-19, 22 and 29. Anti-asparaginase antibody levels were measured on days 1, 15 and 29 of PEG-L-A treatment. Half-lives of l-asparaginase were calculated using previously described methods 35 from a minimum of four time-points. All levels represent the mean of assays run in triplicate. It was intended that all patients had complete blood counts, liver functions, amylase, lipase, total protein, albumin, prothrombin time, partial thromboplastic time, fibrinogen, and antithrombin III levels checked every 2 weeks while receiving the drug.
Statistical methods
Exact
2 tests compared categorical characteristics of patients receiving and not receiving asparaginase. t-Tests and the Wilcoxon two-sample tests compared the age distribution of patients receiving and not receiving asparaginase, as well as the antibody levels of patients with and without prior allergy.
Results
Toxicity
The toxicities seen in this trial are listed in Table 3 . They were similar to those described previously for PEG-L-A. 31, 34 Of the 24 patients treated with the drug, five developed allergic reactions. Two had both wheezing and skin rash, and the drug was discontinued after each had received three doses. One developed urticaria and facial swelling after the fourth dose and therapy was stopped. One developed urticaria after the third dose, but went on to complete a total of 12 doses with diphenhydramine therapy before and after each subsequent treatment. One developed wheezing and cyanosis just after the 12th dose. Two of these five patients had demonstrated previous allergic reactions to E. coli and/or Erwinia asparaginase; of the other 19 patients treated with PEG-L-A, four had had previous allergic reactions to E. coli asparaginase. Two of the 24 patients developed symptomatic pancreatic disease. One developed moderate abdominal pain, vomiting and an amylase more than twice normal following her third dose of PEG-L-A. Her symptoms resolved over 5 days and she was able to resume treatment 3 weeks after the previous dose and complete the course of 12 treatments. A second patient developed hemorrhagic pancreatitis (amylase Ͼ 1000 IU/ml, lipase Ͼ 300 IU/ml) complicated by severe abdominal pain and vomiting, hypotension, and disseminated intravascular coagulation. He recovered completely, but was not rechallenged with the drug.
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One patient, who was also receiving cyclosporin A and proved to be in relapse, developed paresthesias 3 days after starting PEG-L-A, which may have been related to the drug. No patient developed hyperglycemia. Although coagulation defects were detected in most of the patients tested, no thrombotic events were observed.
Four patients developed complications which resulted in hospitalization, including one with wheezing, one with anorexia/severe weight loss, and two with pancreatitis.
Of the 24 treated patients, nine completed the 12 doses of therapy, and one each received 11, eight, and seven doses. The other 12 received five or fewer doses. The 15 who did not receive the planned 12 doses had treatment terminated due to relapse (11), allergy (three) or pancreatitis (one).
Asparaginase, and anti-asparaginase antibody levels
Nineteen of the 24 patients treated with post-transplant asparaginase were enrolled on a study of the pharmacokinetics of the first dose. Of the 19, two had never been treated with asparaginase, five had prior hypersensitivity reactions to native E. coli asparaginase, and 12 had been treated with native asparaginase without clinical reactions in the past. The mean t 1/2 of PEG-L-A for the 19 patients was 11.5 days, the median 8.9 days, and the range 1.5-36 days. The mean t 1/2 in the five patients with prior allergic reactions to E. coli asparaginase did not differ significantly from the remainder of the group (mean 11.2 vs 11.6 days (P = 0.92 by t-test), median 12.4 vs 8.9 days). Serum asparagine was depleted for more than 14 days in all but three patients, one of whom had a prior allergic reaction to E. coli asparaginase; these three patients had the highest antibody levels during treatment with PEG-L-A detected in our study. Of the three, two developed allergic reactions to PEG-L-A, and the third relapsed after five doses. Sample curves for two patients, one with short and one with prolonged duration of asparaginase depletion are illustrated in Figure 1 .
Five patients who had pharmacokinetic studies performed had had previous hypersensitivity reactions to native asparaginase. In only one were a short t 1/2 (2.3 days) and a short period of asparagine depletion (9 days) documented. Of the five patients in our study who developed hypersensitivity to PEG-L-A, two had pharmacokinetic studies, and both demonstrated short t 1/2 (3.7 and 2.3 days), short periods of asparagine depletion (7 and 9 days), and high anti-asparaginase antibody titers.
Antibody titers against asparaginase were measured in 15 patients. Five of the 15 patients had positive titers prior to starting PEG-L-A, and five others developed positive titers by day 29 of PEG-L-A therapy.
Anti-leukemia efficacy
Since this was a pilot trial, we could not determine if the asparaginase treatment improved the chance of leukemiafree survival. Eight patients, two of 12 autologous and six of 12 allogeneic BMT patients treated with PEG-L-A, survive 20+ to 62+ months after BMT, rates of survival comparable to those for patients reported in other BMT series. Ten of the 24 patients developed relapse while receiving the drug, although all but two of the 10 were in third or later remission or in relapse at the time of BMT.
Of patients in second remission at the time of BMT, five of seven who underwent allogeneic and two of five who underwent autologous remain in CR. The median first remission duration of the seven who remain in CR2 was 29 months (with three patients who had first CR durations beyond 4 years, vs a median of 21 months and no first CR duration beyond 32 months among the five patients who relapsed after BMT). This suggests that, to some extent, the long-term survival seen in this group of patients may have been related to favorable leukemia features.
Discussion
The role of antileukemia chemotherapy following BMT remains to be defined. As noted above, we were able to deliver at least some therapy to over 70% of autologous BMT patients and to over half of allogeneic BMT patients. Since relapse rates are very high in patients undergoing autologous BMT for ALL, the fact that most of our patients were able to start treatment was encouraging. Furthermore, three of the 10 allogeneic BMT patients who did not receive PEG-L-A did not because of problems related at least in part to graft-versus-host disease (GVHD), which in itself is associated with a lower incidence of leukemic relapse. [9] [10] [11] [12] [13] An agent which could provide an antileukemic effect 883 Table 4 Patients treated with PEG-l-asparaginase Patients listed as CCR were in remission as of 1 August 1997. IF = induction failure; Weight = weight loss Ͼ 10%. while offering some degree of GVHD suppression would be ideal for post-transplant therapy. One laboratory study suggested that l-asparaginase showed considerable activity in a rat model following allogeneic BMT against GVHD. 41 Of our 12 patients who received PEG-L-A, only three had any acute GVHD (all stage I) and all had complete resolution by the start of PEG-L-A treatment. Our study was therefore too small to detect an impact of PEG-L-A on GVHD.
The pharmacokinetic profiles obtained for this group of patients were similar to those seen in non-transplanted patients, [35] [36] [37] [38] and suggest that in our study PEG-l-asparaginase retained one of its most useful properties, the need for relatively infrequent injections. The long-term survival of two of five patients undergoing autologous and five of seven patients undergoing allogeneic BMT in second remission is promising but must be tempered by the fact that the median duration of the first remission for the seven survivors was 29 months, which of itself would suggest that this patient group had a favorable prognosis.
The toxicity of PEG-L-A in this trial was generally tolerable in patients able to receive the drug. Whereas most patients beyond CR2 relapsed while receiving the drug, patients with less advanced disease (CR1 and CR2) often could not meet eligibility requirements to receive the drug or developed toxicities which severely limited the period of treatment. Only nine of 38 patients (24%) overall and eight of 25 (32%) in CR1 or CR2 received the entire 12-treatment regimen. Based on these results, we cannot at this time recommend a phase III trial of single agent, posttransplant PEG-L-A therapy, to a large extent because transplant-related complications limited our ability to deliver the drug. A number of patients did not receive PEG-L-A due to thrombocytopenia; two others did not receive the drug because of recent pancreatitis. In retrospect, the fact that platelet counts continued to rise in most patients despite the PEG-L-A treatment suggest that our requirement for 50 000 platelets prior to the start of PEG-L-A may have been too stringent. The advent of platelet-stimulating growth factors 42, 43 may augment recovery so as to allow more rapid initiation of post-transplant chemotherapy.
Chemoprotectants such as lisofylline, 44 which appear to reduce complications following allogeneic transplantation, might limit other organ toxicities which delayed or prevented the start of PEG-L-A. While our data at this time cannot support the development of phase III trials of PEG-L-A, other advances in the treatment and prevention of post-marrow transplant complications might improve the possibility of delivery of PEG-L-A and allow for future studies of its efficacy.
